Dosage Forms

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

Although shortages, quality, and regulatory challenges remain, improved technologies and new investments suggest that the worst may be over.

Better Days for Parenterals?

Miriam Beyer, European marketing manager, West Pharmaceutical Services, describes causes of recent parenteral drug shortages.

Addressing Parenteral Manufacturing Challenges

Scottish injectable-drug manufacturer Symbiosis Pharmaceutical Services plans to expand its sterile filling facility.

CMO Symbiosis Expands Scotland Facility

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

The challenge of achieving zero visible defects (i.e., particulates) in parenteral drugs will require a coordinated effort at all stages of the supply chain, particularly in the production and filling of primary containers.

Partnering to Address Particulates

Hallie Forcinio is packing editor for Pharmaceutical Technology and Pharmaceutical Technology Europe, editorhal@sbcglobal.net.

Manufacturers of parenteral drugs face challenges to increase efficiency, control particulates, control extractables and leachables, and eliminate product/package interactions; new containers and packaging equipment offer increased options.

Parenteral Packaging Advances

GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications.

Self-Contained Laboratory Homogenizer Prepares Injectable Drugs

FDA warns that compounded or repackaged drugs stored in certain syringes made by Becton-Dickinson may lose potency because of an interaction with the rubber stopper.

FDA Expands Warning on BD Syringes

Operator attention to detail and adherence to procedures are crucial for proper cleaning.

Cleaning a Vial Filling Line

GEA's self-contained homogenizer is designed for laboratory applications, including cell dispersions.

The company’s Scotland-based facility has successfully completed a scheduled inspection by the UK’s MHRA; there were no critical or major observations noted.

Parenterals and Injectables